How Lipid Metabolism May Shape Multiple Sclerosis Severity: Genetic Evidence from Mendelian Randomization
Multiple sclerosis (MS) is characterized not only by heterogeneous clinical manifestations but also by striking variability in long-term disability and disease progression. The biological mechanisms responsible for this variation remain incompletely defined. Metabolomics has become increasingly valuable in this context because circulating metabolites represent integrated products of genetic regulation, environmental exposures, immune activity, cellular energetics, and intermediary metabolism. However, conventional observational studies cannot readily determine whether metabolic abnormalities contribute to disease progression or instead emerge as consequences of more severe disease. The study by Noroozi and colleagues, Integrative Genetic Analyses of Lipid Metabolism and Multiple Sclerosis Severity Using Metabolome-Wide and Cis-Mendelian Randomization, addresses this problem through an extensive genetic framework designed to move from metabolic association toward causal inference. The investigators report that genetically determined differences in several lipid and amino-acid pathways are related to MS severity, with particularly strong evidence converging on polyunsaturated fatty-acid (PUFA) metabolism and the FADS1/2 and CYP4F2 loci. Their central interpretation is that altered PUFA processing, especially reduced FADS1 activity, may participate directly in the biological processes determining MS severity rather than simply accompanying them. Importantly, the manuscript is a medRxiv preprint and has not yet undergone peer review.
Mendelian Randomization as a Tool for Investigating MS Progression
The study employed Mendelian randomization (MR), an instrumental-variable approach in which genetic variants associated with an exposure—in this case circulating metabolite concentrations—are used to estimate the effect of that exposure on an outcome. Because inherited variants are established at conception, MR can reduce some of the confounding and reverse-causation problems that complicate conventional metabolomic studies. The investigators analyzed metabolomic GWAS data encompassing 1,091 plasma metabolites and 309 metabolite ratios measured in 8,299 participants from the Canadian Longitudinal Study on Aging. MS severity was evaluated using GWAS summary statistics from 12,584 people with MS of European ancestry. The outcome was the age-related multiple sclerosis severity score (ARMSS), a measure integrating disability, quantified by the Expanded Disability Status Scale, with age. The analytical strategy was considerably more comprehensive than a single MR test. It incorporated inverse-variance weighted MR, MR-Egger and other complementary estimators, tests for heterogeneity and horizontal pleiotropy, leave-one-out analyses, Steiger filtering and reverse MR. Pathway-specific multivariable MR was then used to distinguish the independent effects of correlated metabolites, while genetic colocalization and cis-MR were applied to identify plausible genes and enzymatic mechanisms underlying the observed associations.
A Metabolome-Wide Signal Spanning Lipids and Amino Acids
The first stage of the analysis demonstrated that the relationship between metabolism and MS severity is not restricted to a single molecule. The primary inverse-variance weighted analysis identified 45 metabolites with nominally significant associations, including 36 annotated metabolites or ratios and nine uncharacterized compounds. Robustness testing strengthened several of these observations: 40 of the nominally significant metabolites showed concordant directions of effect under MR-Egger analysis, while most displayed no evidence of substantial heterogeneity. Steiger filtering generally supported the proposed direction from metabolite variation to MS severity, and reverse MR produced little evidence that greater MS severity was itself responsible for the identified metabolic changes, with decadienedioic acid representing an exception. Because metabolite concentrations are highly correlated, the investigators subsequently applied pathway-specific multivariable MR. This analysis identified significant independent effects for three amino-acid-related and two fatty-acid-related metabolites, suggesting that the initial signals did not merely reflect broad correlation within biochemical networks. Collectively, these results positioned lipid metabolism—and fatty-acid biology in particular—as a major candidate pathway, while also indicating contributions from amino-acid and energy metabolism.
FADS1 Emerges as a Central Regulator of PUFA-Related Effects
The most mechanistically coherent finding arose from the FADS1/FADS2 region on chromosome 11, a locus with an established role in PUFA biosynthesis. Genetic colocalization showed that several fatty-acid-related metabolite ratios and MS severity appeared to share genetic signals within a region containing FADS1, FADS2, MYRF, and TMEM258. Among the implicated signals, rs174564 was identified as a putative shared causal variant for FADS1/2-related associations, while neighboring variants associated with MYRF and TMEM258 were in very strong linkage disequilibrium with this signal. The investigators therefore moved beyond locus-level association by using the functional variant rs174546C>T as a cis-instrument for FADS1 perturbation. The T allele is associated with repression of FADS1 expression and reduced Δ5-desaturase activity. The resulting metabolic pattern is biologically informative: upstream intermediates associated with FADS2 activity accumulate, whereas downstream products requiring FADS1 activity decline. When these pathway-resolved metabolites were examined by cis-MR, both components of this biochemical signature pointed in the same direction—genetically proxied reduction of FADS1 activity was associated with greater MS severity. This biochemical consistency is important because it links a genetic perturbation, a known enzyme, a predictable metabolic signature, and a clinical phenotype within a single causal model.
Evidence Extends from Circulation to Brain Cells and CYP4F2
A particularly notable aspect of the study is that the FADS1 signal was not confined to circulating metabolites. Using rs174546 as an expression quantitative trait locus, the investigators performed cell-type-specific cis-MR across seven brain cell populations. Reduced FADS1 expression associated with the variant was observed in astrocytes, oligodendrocytes, inhibitory neurons, and excitatory neurons, and genetically predicted lower expression in these cell types was associated with increased MS severity. Colocalization analyses further supported the possibility that metabolite concentrations, MS severity, and cell-specific FADS1 expression share an underlying causal genetic signal. The analysis also identified a second PUFA-related candidate gene, CYP4F2. At this locus, circulating succinoyltaurine and MS severity showed moderate evidence of colocalization involving rs2108622, a missense variant associated with reduced CYP4F2 protein levels. Cis-MR analyses of metabolites downstream of CYP4F2 activity suggested that genetically proxied reductions in enzyme activity were likewise associated with greater MS severity. Although the CYP4F2 evidence was less definitive than that surrounding FADS1, the convergence of two independent PUFA-metabolizing enzymes strengthens the broader hypothesis that disturbed fatty-acid processing may influence the biological course of MS.
Beyond Fatty Acids: Mitochondrial and Amino-Acid Metabolism
The metabolome-wide analysis also suggests that MS severity may reflect broader metabolic alterations rather than an isolated disturbance of PUFA synthesis. Associations involving α-ketoglutarate, the α-ketoglutarate-to-proline ratio, and several metabolites related to succinyl-CoA point toward mitochondrial energy metabolism as another potentially relevant biological domain. Amino-acid-related signals were also observed. The study reports associations of arginine and the serine-to-pyruvate ratio with greater MS severity, whereas genetically predicted betaine levels were associated with reduced severity. Betaine is particularly interesting because it functions as a methyl donor and is involved in metabolic pathways connecting lipid oxidation, one-carbon metabolism, and phospholipid homeostasis; the authors relate their genetic finding to earlier experimental evidence suggesting potentially neuroprotective effects. These secondary findings should be interpreted more cautiously than the FADS1 results because they did not receive the same degree of pathway-resolved colocalization and functional cis-MR support. Nevertheless, they illustrate an important feature of MS biology: neurological disability may emerge from interactions among immune signaling, membrane lipid composition, mitochondrial bioenergetics, and amino-acid metabolism rather than from a single molecular abnormality.
Scientific Significance, Limitations, and Translational Perspective
The principal contribution of this study is its integration of several levels of genetic evidence. Metabolome-wide MR provided broad screening; sensitivity and reverse-direction analyses tested the robustness of causal inference; multivariable MR addressed correlated metabolites; colocalization assessed whether metabolite and MS signals could originate from shared variants; functional cis-MR connected these variants to specific enzymes; and single-cell analyses extended the FADS1 hypothesis into relevant brain cell populations. The authors therefore argue that genetically driven dysregulation of PUFA metabolism, particularly reduced FADS1 activity, contributes to variation in MS severity. There are, however, important limitations. The GWAS datasets were restricted to individuals of European ancestry, limiting generalizability, and the authors emphasize the need for replication in diverse populations as well as age- and sex-stratified analyses. Experimental and clinical studies will also be required to determine precisely how alterations in FADS1 or CYP4F2 affect inflammatory signaling, neuronal function, membrane composition, and disability progression. Consequently, the paper should not be interpreted as evidence that omega-3, PUFA, betaine, or other supplementation currently constitutes a treatment for MS progression. Rather, it provides a genetically informed mechanistic framework that identifies PUFA metabolism as a promising target for future biological validation, biomarker development, patient stratification, and eventually intervention studies.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Noroozi, R., Higgins Tejera, C., Chen, M., Briggs, F. B., Bhargava, P., & Fitzgerald, K. C. (2026). Integrative Genetic Analyses of Lipid Metabolism and Multiple Sclerosis Severity Using Metabolome-Wide and Cis-Mendelian Randomization. medRxiv, 2026-05.
